SCHEDULE: NeuroOne Medical Technologies Corp. - Beneficial Ownership Filing

Brian and Barbara Pratt jointly report beneficial ownership of 1,085,934 shares, representing 12.5% of NeuroOne Medical Technologies Corporation's common stock.

Summary

• Brian Pratt and Barbara Pratt have jointly filed a Schedule 13G, indicating their beneficial ownership of NeuroOne Medical Technologies Corporation's common stock.
• They collectively own 1,085,934 shares of common stock.
• This holding represents 12.5% of the company's outstanding common stock.
• The shares are held in a joint account.
• The filing is an amendment to a previous filing, with the event date requiring this statement being July 10, 2026.
• The outstanding shares figure used for the percentage calculation is based on the company's Quarterly Report on Form 10-Q filed on June 12, 2026, which reported 8,702,982 shares outstanding as of June 10, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial information about the company itself.

Positives

• The Pratts' joint filing clarifies their significant beneficial ownership stake, providing transparency to the market.
• The filing confirms a substantial holding of 12.5% of the company's outstanding shares.

Risks

• While this filing primarily concerns ownership, any significant shift in beneficial ownership could be perceived as a signal of changing investor sentiment or strategy, which could indirectly impact the stock price.
• The filing does not provide insight into the Pratts' intentions regarding their stake, leaving potential future actions open to speculation.

Future Outlook

This filing does not contain forward-looking statements or guidance from the company. It solely pertains to the reporting of beneficial ownership.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for significant beneficial ownership changes or confirmations. For NeuroOne Medical Technologies Corporation, a company in the medical technology sector, such filings are crucial for market transparency regarding major shareholders.

Stakeholder Impact

• Shareholders gain clarity on a significant beneficial owner's stake, which can influence perceptions of company stability and future direction.
• The market receives transparent information regarding ownership concentration.

Next Steps

• The Pratts will continue to report any further changes in their beneficial ownership as required by SEC regulations.
• The company's ongoing operations and financial performance will be detailed in subsequent SEC filings.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, NeuroOne Medical Technologies Corporation, Common Stock, Joint Filing, SEC Filing, Investment Holding, Shareholder